May 2015, Vol 5, No 4

FDA-Approved Medications Used for the Treatment of Leukemia

The following sections will assist healthcare professionals and payers by providing appropriate coding and billing information associated with the treatment of leukemia. Read More ›

Akynzeo (Netupitant and Palonosetron), a Dual-Acting Oral Agent, Approved by the FDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting

By Lisa A. Raedler, PhD, RPh

Drug Updates

May 2015, Vol 5, No 4

Trials Under Way for Patients with Melanoma

Clinical Trials Tracker

May 2015, Vol 5, No 4

Seven Steps to Finding the Right Financial Advisor

By W. Ben, Utley, CFP; Lawrence B. Keller, CFP, CLU, ChFC, RHU, LUTCF

Financial Management, Practice Management, Practice Management

May 2015, Vol 5, No 4

Rest in Peace, SGR

By Leah Ralph

May 2015, Vol 5, No 4

Sunitinib Associated with Higher Costs Compared with Pazopanib in Patients with RCC

By Chase Doyle

Drug Updates

May 2015, Vol 5, No 4

Federal Government Outlines Stage 3 of Meaningful Use

By Rosemary Frei, MSc

Reimbursement

May 2015, Vol 5, No 4

Waiting for the Carrot? It May Take a While

By Dawn Holcombe, MBA, FACMPE, ACHE

From the Editor

May 2015, Vol 5, No 4

The Nurse Practitioner’s Role in the Practice

By Peggy Barton, RN

Practice Management

May 2015, Vol 5, No 4

340B Rules Remain in Flux

By Rosemary Frei, MSc

May 2015, Vol 5, No 4

May 2015, Vol 5, No 4

Page 1 of 2